Genomic profiling in triple-negative breast cancer

Breast Care

Volumn 8, Issue 6, 2013, Pages 408-413

  Liedtke, Cornelia ^a   Bernemann, Christof ^b   Kiesel, Ludwig ^b   Rody, Achim ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Heterogeneity; RNA profiling; Triple negative breast cancer, subtypes; Whole genome sequencing

Indexed keywords

CANCER STEM CELL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; PRIORITY JOURNAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; DISEASE ASSOCIATION; DNA METHYLATION; GENE DOSAGE; GENE MUTATION; HORMONAL THERAPY; NEXT GENERATION SEQUENCING; TUMOR ASSOCIATED LEUKOCYTE;

CAPECITABINE; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; GENOMIC DNA; INIPARIB; KI 67 ANTIGEN; MESSENGER RNA; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; VIMENTIN;

EID: 84892376837     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000357534     Document Type: Review

References (50)

1. Gluz O, Liedtke C, Gottschalk N, et al.: Triplenegative breast cancer - current status and future directions. Ann Oncol 2009;20: 1913-1927.
2. Carey L, Winer E, Viale G, et al.: Triple-negative breast cancer: Disease entity or title of convenience? Nat Rev Clin Oncol 2010;7: 683-692.
3. Heitz F, Harter P, Lueck HJ, et al.: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009;45: 2792-2798.
4. Liedtke C, Hess KR, Karn T, et al.: The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat 2013;138: 591-599.
5. Perou CM, Sørlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
6. Sorlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98: 10869-10874.
7. Carey L.A, Perou CM, Livasy CA, et al.: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295: 2492-2502.
8. Nofech-Mozes S, Trudeau M, Kahn HK, et al.: Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 2009;118: 131-137.
9. Prat A, Adamo B, Cheang MC, et al.: Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013; 18: 123-133.
10. Cheang MC, et al.: Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. J Clin Oncol 2012;30(Suppl): abstr 1008.
11. Iwamoto T, Booser D, Valero V, et al.: Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ERpositive by immunohistochemistry. J Clin Oncol 2012;30: 729-734.
12. Liedtke C, Mazouni C, Hess KR, et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26: 1275-1281.
13. Carey LA, Dees EC, Sawyer L, et al.: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13: 2329-2334.
14. Shah SP, Roth A, Goya R, et al.: The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 2012;486: 395-399.
15. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012;490: 61-70.
16. Lehmann BD, Bauer JA, Chen X, et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121: 2750-2767.
17. Masuda H, Baggerly KA, Wang Y, et al.: Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. J Clin Oncol 2013; 31(Suppl):abstr 1005.
18. Telli ML, et al.: PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer. J Clin Oncol 2013;31:abstr 1003.
19. Rody A, Karn T, Liedtke C, et al.: A clinically relevant gene signature in triple negative and basallike breast cancer. Breast Cancer Res 2011;13:R97.
20. Denkert C, Loibl S, Müller BM, et al.: Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant Gepar- Trio trial. Cancer Res 2012;72(24 Suppl):102s.
21. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100: 3983-3988.
22. Korkaya H, Paulson A, Iovino F, et al.: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008;27: 6120-6130.
23. Schatton T, Murphy GF, Frank NY, et al.: Identification of cells initiating human melanomas. Nature 2008;451: 345-349.
24. Gupta PB, Onder TT, Jiang G, et al.: Identification of selective inhibitors of cancer stem cells by highthroughput screening. Cell 2009;138: 645-659.
25. Witkiewicz AK, Dasgupta A, Sotgia F, et al.: An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009;174: 2023-2034.
26. Ginestier C, Hur MH, Charafe-Jauffret E, et al.: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555- 567.
27. Honeth G, Bendahl PO, Ringnér M, et al.: The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008;10:R53.
28. Foulkes WD, Smith IE, Reis-Filho JS : Triple-negative breast cancer. N Engl J Med;363: 1938-48.
29. Tan EY, Thike AA; Breast Surgical Team at Outram, et al.: ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome. Br J Cancer 2013;109: 109-113.
30. Ricardo S, Vieira AF, Gerhard R,et al.: Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 2011;64: 937-946.
31. Charafe-Jauffret E, Ginestier C, Iovino F, et al.: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302- 1313.
32. Prince ME, Sivanandan R, Kaczorowski A, et al.: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104: 973-978.
33. Singh SK, Hawkins C, Clarke ID, et al.: Identification of human brain tumour initiating cells. Nature 2004;432: 396-401.
34. Hermann PC, Huber SL, Herrler T, et al.: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1: 313-323.
35. Wang XY, Penalva LO, Yuan H, et al.: Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. Mol Cancer 2010;9:221.
36. Nakshatri H, Srour EF, Badve S: Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 2009;4: 50-60.
37. Yang J, Mani SA, Donaher JL, et al.: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117: 927-939.
38. Thiery JP, Acloque H, Huang RY, et al.: Epithelial- mesenchymal transitions in development and disease. Cell 2009;139: 871-890.
39. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 2007;7: 415-428.
40. Mani SA, Guo W, Liao MJ, et al.: The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008;133: 704-715.
41. Maestro R, Dei Tos AP, Hamamori Y, et al.: Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13: 2207-2217.
42. Morel AP, Lièvre M, Thomas C, et al.: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3:e2888.
43. Aomatsu N, Yashiro M, Kashiwagi S, et al.: CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One 2012;7:e45865.
44. Chaffer CL, Brueckmann I, Scheel C, et al.: Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011;108: 7950-7955.
45. Gupta PB, Fillmore CM, Jiang G, et al.: Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011;146:633- 644.
46. Karihtala P, Auvinen P, Kauppila S, et al.: Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: Association with an aggressive tumour phenotype. Breast Cancer Res Treat 2013;138: 81-90.
47. Liu T, Zhang X, Shang M, et al.: Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J Surg Oncol 2013;107: 188-194.
48. Proia TA, Keller PJ, Gupta PB, et al.: Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011; 8: 149-163.
49. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, et al.: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008;68: 989-997.
50. Yamashita N, Tokunaga E, Kitao H, et al.: Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol 2013; 139: 739-746.